SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Advances Against Aspergillosis And Mucormycosis Conference, January 25 – 27, in Milan, Italy
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.
| Poster Presentation: | ||
| Title: | SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis | |
| Presenting author: | Dr. Ashraf Ibrahim, PhD, FAAM, FECCM (Professor of Medicine, Division of Infectious Disease, David Geffen School of Medicine UCLA) | |
In this preclinical study, SCY-247 demonstrated in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice. Notably, the combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy.
"The results from this preclinical study are very encouraging and illustrate the significant potential for this novel fungerp candidate SCY-247," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. "Groundbreaking treatment options are urgently needed to address the significant limitations in effective therapies for devastating and very often lethal fungal diseases such as mucormycosis. We continue to expeditiously progress the development of this promising antifungal with plans to begin a clinical study by year end."
For more information, see the AAAM website here.
The study was funded by the National Institutes of Health (NIH) under NIH Task order A65 75N93022F00001 utilizing the National Institute of Allergy and Infectious Diseases (NIAID) suite of preclinical services for in vivo testing.
About SCY-247
SCY-247 is a second generation antifungal compound, from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), under development as therapeutic options for systemic fungal diseases. The triterpenoid class of antifungals represents the first new class of antifungal compounds since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. SCY-247 is in pre-IND development stage and has demonstrated broad-spectrum antifungal activity, in vitro and in vivo. SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247.